Results 41 to 50 of about 114,366 (208)

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook, Veerain Gupta, Nicholas J. Clark, Vijay Rings, Lauren E. Corona, Douglass B. Clayton, Daniel J. Benedetti   +6 more
wiley   +1 more source

Patient decision aids in colorectl cancer: a review

Psicooncologia, 2010
Aim: The objective is to collect available patient decision aids (PDA) for colorectal cancer in any of the stages of the disease and to gather published studies about the use of these tools in the last ten years Methods: A systematic review (SR) of tools
María Soriano, Juan Antonio Blasco, Fátima Izquierdo, Mercedes Guerra   +3 more
doaj  

Method for Developing Patient Decision Aid in China

Xiehe Yixue Zazhi
Objective To systematically construct a guideline to provide a methodological guide for researchers to develop patient decision aids. Methods Through a literature review of international methodological guidance for developing patient decision aids ...
LU Yao, ZHANG Qian, CHENG Qianji, LIU Jianing, SUN Mingyao, NING Jinling, HUANG Jiajie, REN Simeng, ZHANG Wenzheng, LIU Yajie, DENG Xiyuan, TIAN Jinhui, LIU Jie, GE Long   +13 more
doaj   +1 more source

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) is assessed by cell counting and cytomorphology from cerebrospinal fluid (CSF) and is used for treatment stratification worldwide. The ratio of “CNS2” patients in clinical trials ranges from 3% to 40%, with unclear prognostic significance ...
Laura Almási, Bernadett Borbála Huszti, Gábor Barna, Marko Kavcic, Janez Jazbec, Lennart Lenk, Vera Münch, Sophia Polychronopoulou, Ágnes Márk, Maria Thastrup, Lüder H. Meyer, Kjeld Schmiegelow, Cornelia Eckert, Christina Halsey, Dániel J. Erdélyi   +14 more
wiley   +1 more source

Increased Risk of Sarcomas in Children With Congenital Anomalies: Findings From the Genetic Overlap Between Anomalies and Cancer in Kids (GOBACK) Registry Linkage Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Pediatric sarcomas are a heterogeneous group of tumors that contribute disproportionately to cancer mortality in children. Although congenital anomalies are among the strongest known risk factors for childhood cancer, the risk of specific sarcoma subtypes among affected individuals has not yet been thoroughly evaluated. Procedure We
Russ Wolters, Ji Yun Tark, Tiffany M. Chambers, Tania A. Desrosiers, Michael E. Scheurer, Charles Shumate, Wendy N. Nembhard, Mahsa M. Yazdy, Eirini Nestoridi, Amanda E. Janitz, Jean Paul Tanner, Russell S. Kirby, Jason L. Salemi, Yao Yu, Chad D. Huff, Sharon E. Plon, Philip J. Lupo, Jeremy M. Schraw   +17 more
wiley   +1 more source

Supporting Survivor‐Centered Care Through Digital Health Integration

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Survivors of childhood cancer face barriers to receiving guideline‐based, long‐term follow‐up care. Two digital tools, Passport for Care (PFC) and Cancer SurvivorLink (SurvivorLink), address complementary gaps by enabling tailored survivorship care plan (SCP) generation, updating, storage, and sharing.
Jordan G. Marchak, Rebecca Williamson‐Lewis, Michael O'Connor, Michael Palgon, Yu‐Ra Kim, Michael Schuckenbrock, Paula Edwards, Abraham Mendoza, Anthony Adams, Brian Arriaga‐Solis, Justin Parker, Harry Tinoco‐Giraldo, Jason King, C. Michael Fordis, Karen E. Effinger, Maria Monica Gramatges   +15 more
wiley   +1 more source

The impact of decision aids to enhance shared decision making for diabetes (the DAD study): protocol of a cluster randomized trial

BMC Health Services Research, 2012
Background Shared decision making contributes to high quality healthcare by promoting a patient-centered approach. Patient involvement in selecting the components of a diabetes medication program that best match the patient’s values and preferences may ...
LeBlanc Annie, Ruud Kari L, Branda Megan E, Tiedje Kristina, Boehmer Kasey R, Pencille Laurie J, Van Houten Holly, Matthews Marc, Shah Nilay D, May Carl R, Yawn Barbara P, Montori Victor M   +11 more
doaj   +1 more source

Using Nudges to Enhance Clinicians’ Implementation of Shared Decision Making With Patient Decision Aids

MDM Policy & Practice, 2020
Background. Although effective interventions for shared decision making (SDM) exist, there is a lack of uptake of these tools into clinical practice. “Nudges,” which draw on behavioral economics and target automatic thinking processes, are used by policy
Kristin M. Kostick, Meredith Trejo, Robert J. Volk, Jerry D. Estep, J.S. Blumenthal-Barby   +4 more
doaj   +1 more source

Efficacy and Safety Analysis of Roxarestat in Regulating Renal Anemia in Patients on Maintenance Hemodialysis

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley   +1 more source

Therapeutic Apheresis for Intravenous Methylprednisolone‐Refractory Neuromyelitis Optica Spectrum Disorder: Clinical and Radiological Outcomes in a Single‐Center Case Series

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system. High‐dose intravenous methylprednisolone (IVMP) is the standard first‐line therapy for acute attacks, although some patients remain refractory.
Wataru Horiguchi, Daisuke Katagiri, Takeyuki Watadani, Shunichi Matsuda, Hiroshi Kaneko, Noritoshi Arai   +5 more
wiley   +1 more source